Pfizer (UKEX:PFE) Cyclically Adjusted Revenue per Share: ₴517.95 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:PFE Pfizer Inc UKEX:PFE
67 GF Score
Price ₴1,014.00
GF Value ₴940.84
! 8 Warning Signs
View Full Analysis

What is Pfizer Cyclically Adjusted Revenue per Share?

Pfizer UKEX:PFE 67 Cyclically Adjusted Revenue per Share is ₴517.95 as of Jun. 2026. GuruFocus rates UKEX:PFE with a GF Score™ of 67/100 and a GF Value™ of ₴940.84. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pfizer's adjusted revenue per share for the three months ended in Jun. 2026 was ₴117.795. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₴517.95 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pfizer's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pfizer was 13.90% per year. The lowest was -0.10% per year. And the median was 5.20% per year.

As of today (2026-09-02), Pfizer's current stock price is ₴1014.00. Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₴517.95. Pfizer's Cyclically Adjusted PS Ratio of today is 1.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 3.99.


Pfizer  (UKEX:PFE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pfizer's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1014.00/517.95
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pfizer was 6.59. The lowest was 1.85. And the median was 3.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pfizer Cyclically Adjusted Revenue per Share Related Terms


Pfizer Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted Revenue per Share Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 426.72 445.66 488.67

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 498.63 478.74 488.67 440.19 517.95

UKEX:PFE vs GILD, BMY, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.


UKEX:PFE
67GF Score
Pfizer Inc UKEX:PFE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=117.795/333.9520*333.9520
=117.795

Current CPI (Jun. 2026) = 333.9520.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 94.715 241.428 131.013
201612 99.579 241.432 137.739
201703 93.667 243.801 128.303
201706 95.386 244.955 130.042
201709 97.333 246.819 131.694
201712 100.953 246.524 136.755
201803 95.144 249.554 127.321
201806 101.024 251.989 133.883
201809 99.197 252.439 131.228
201812 8.721 251.233 11.592
201903 101.871 254.202 133.831
201906 104.421 256.143 136.141
201909 100.230 256.759 130.364
201912 14.617 256.974 18.996
202003 80.213 258.115 103.780
202006 78.387 257.797 101.543
202009 81.466 260.280 104.525
202012 90.118 260.474 115.540
202103 114.479 264.877 144.333
202106 148.625 271.696 182.681
202109 187.464 274.310 228.223
202112 184.541 278.802 221.045
202203 198.999 287.504 231.148
202206 216.870 296.311 244.419
202209 176.784 296.808 198.908
202212 195.361 296.797 219.818
202303 144.126 301.836 159.461
202306 101.655 305.109 111.265
202309 106.705 307.789 115.775
202312 114.259 306.746 124.393
202403 116.613 312.332 124.685
202406 104.130 314.175 110.685
202409 138.545 315.301 146.740
202412 139.087 315.605 147.173
202503 107.253 319.799 112.000
202506 114.668 322.561 118.717
202509 130.145 324.800 133.812
202512 137.010 324.054 141.195
202603 112.587 330.213 113.862
202606 117.795 333.952 117.795

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₴517.95 mean?
Pfizer (UKEX:PFE) has a Cyclically Adjusted Revenue per Share of ₴517.95 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors.
Is Pfizer's Cyclically Adjusted Revenue per Share too high?
Pfizer's current Cyclically Adjusted Revenue per Share is ₴517.95. Overall, Pfizer has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Cyclically Adjusted Revenue per Share compare to GILD and BMY?
Pfizer's Cyclically Adjusted Revenue per Share of ₴517.95 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pfizer and its competitors. Pfizer's current Cyclically Adjusted Revenue per Share is ₴517.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Pfizer (UKEX:PFE) has a current Cyclically Adjusted Revenue per Share of ₴517.95. The stock's GF Value™ is ₴940.84, compared to a current price of ₴1,014.00 — trading 7.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₴517.95. Pfizer's overall GF Score™ is 67/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pfizer (UKEX:PFE), the current Cyclically Adjusted Revenue per Share is ₴517.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (UKEX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be overvalued. The current stock price of ₴1,014.00 is trading 7.8% above its estimated GF Value™ of ₴940.84.

Key valuation signals for UKEX:PFE:

  • Cyclically Adjusted Revenue per Share: ₴517.95
  • GF Value™: ₴940.84 vs. price of ₴1,014.00 (7.8% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the UKEX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
67GF Score

Get the complete analysis for UKEX:PFE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴1,014.00
Price
₴940.84
GF Value